文献速递肝病消化道肿瘤与早癌

基于MAPI分型的脂肪性肝病亚型长期主要不良肝脏结局与肿瘤结局

Long-Term Major Adverse Liver Outcomes and Oncological Outcomes Across Steatotic Liver Disease Subtypes Classified Using the MetALD-ALD Prediction Index.
PubMed 文献 · Aliment Pharmacol Ther · 2026-09-07

在UK Biobank的138,996名基线SLD且无癌症参与者中,按MAPI与自报饮酒量分为MASLD、MetALD、ALD。以MASLD为参照,MetALD全癌及肝外癌风险升高,ALD的MALO、全癌、癌相关死亡、HCC、肝外癌及除外HCC的消化道癌风险均最高。

要点

  • 基于MAPI的SLD分型可区分不同亚型的长期肝脏与肿瘤风险。
  • MetALD较MASLD全癌和肝外癌风险升高,但MALO等未显著升高。
  • ALD较MASLD的MALO、HCC、消化道癌等风险最高。

核心结论

  • MAPI-informed SLD subtypes showed distinct risk profiles.
  • MetALD exhibited higher risks of all cancers and extrahepatic cancers.
  • ALD conferred the highest risks across MALO and cancer outcomes, particularly for HCC and digestive cancer.

研究设计与样本

  • Participants with SLD at baseline and free of cancer in the UK Biobank were classified as MASLD, MetALD, or ALD.
  • Among 138,996 participants, 51,633 were classified as MASLD, 27,231 as MetALD, and 60,132 as ALD.
  • Multivariable Cox models estimated hazard ratios (HRs) and 95% confidence intervals (CIs), with MASLD as the reference group.

主要发现

  • Compared with MASLD, MetALD exhibited higher risks of all cancers (HR, 1.07; 95% CI, 1.04-1.11) and extrahepatic cancers (HR, 1.07; 95% CI, 1.03-1.11), but not of MALO, cancer-related death, HCC, or digestive cancers excluding HCC.
  • ALD showed increased risks of MALO (HR, 1.70; 95% CI, 1.54-1.88), all cancers (HR, 1.12; 95% CI, 1.08-1.15), cancer-related death (HR, 1.07; 95% CI, 1.01-1.14), HCC (HR, 3.07; 95% CI, 2.23-4.23), extrahepatic cancers (HR, 1.11; 95% CI, 1.08-1.14), and digestive cancers excluding HCC (HR, 1.20; 95% CI, 1.11-1.29).

临床怎么用

  • 临床可依据MAPI与自报饮酒量对SLD进行亚型划分,以识别MetALD和ALD等高风险人群。
  • 对MetALD患者应关注全癌及肝外癌风险,对ALD患者应重点关注MALO、HCC及消化道癌风险。

局限性

  • 酒精摄入采用自报方式,可能存在低报并导致分型错分。
  • 研究基于UK Biobank队列,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term adverse liver and oncological risks across steatotic liver disease (SLD) subtypes remain uncertain, and alcohol underreporting may cause misclassification. AIMS: To evaluate long-term risks of major adverse liver outcomes (MALO) and cancer across SLD subtypes by the MetALD-ALD Prediction Index (MAPI) and self-reported alcohol intake. METHODS: Participants with SLD at baseline and free of cancer in the UK Biobank were classified as MASLD, MetALD, or ALD. The primary outcome was incident MALO. Secondary outcomes included incident all cancers, cancer-related death, hepatocellular carcinoma (HCC), extrahepatic cancers, digestive cancers excluding HCC, and site-specific digestive cancers. Multivariable Cox models estimated hazard ratios (HRs) and 95% confidence intervals (CIs), with MASLD as the reference group. RESULTS: Among 138,996 participants, 51,633 were classified as MASLD, 27,231 as MetALD, and 60,132 as ALD. Compared with MASLD, MetALD exhibited higher risks of all cancers (HR, 1.07; 95% CI, 1.04-1.11) and extrahepatic cancers (HR, 1.07; 95% CI, 1.03-1.11), but not of MALO, cancer-related death, HCC, or digestive cancers excluding HCC. ALD showed the greatest risks, with increased risks of MALO (HR, 1.70; 95% CI, 1.54-1.88), all cancers (HR, 1.12; 95% CI, 1.08-1.15), cancer-related death (HR, 1.07; 95% CI, 1.01-1.14), HCC (HR, 3.07; 95% CI, 2.23-4.23), extrahepatic cancers (HR, 1.11; 95% CI, 1.08-1.14), and digestive cancers excluding HCC (HR, 1.20; 95% CI, 1.11-1.29). CONCLUSIONS: MAPI-informed SLD subtypes showed distinct risk profiles. MetALD exhibited higher risks of all cancers and extrahepatic cancers, whereas ALD conferred the highest risks across MALO and cancer outcomes, particularly for HCC and digestive cancer.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Li Y, Huo Z, Liu H, et al. Long-Term Major Adverse Liver Outcomes and Oncological Outcomes Across Steatotic Liver Disease Subtypes Classified Using the MetALD-ALD Prediction Index. Aliment Pharmacol Ther. 2026. PMID: 42703646. doi:10.1111/apt.70967

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。